Jefferies notes that the Centers for Medicare & Medicaid Services announced the launch of a new Accountable Care Organization model: the Long-term Enhanced ACO Design, or LEAD, model. Broadly, the firm views this as a “clear positive” for VBC providers participating in ACO programs like Astrana Health (ASTH), Agilon Health (AGL) and Privia Health (PRVA). The firm has Buy ratings on Astrana and Privia and a Hold rating on Agilon.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASTH:
- Astrana Health initiated with a Buy at Needham
- Astrana Health Positioned for Aggressive Growth and Valuation Upside Amidst Strong Financials and Market Opportunities
- Astrana Health price target lowered to $37 from $44 at Jefferies
- Astrana Health price target lowered to $26 from $36 at Barclays
- Astrana Health price target lowered to $35 from $40 at TD Cowen
